MCID: LYM007
MIFTS: 65

Lymphangioleiomyomatosis malady

Categories: Genetic diseases, Rare diseases, Respiratory diseases, Immune diseases

Aliases & Classifications for Lymphangioleiomyomatosis

About this section
Sources:
50OMIM, 11Disease Ontology, 46NIH Rare Diseases, 24Genetics Home Reference, 13DISEASES, 52Orphanet, 68UniProtKB/Swiss-Prot, 12diseasecard, 48Novoseek, 66UMLS, 25GTR, 43NCIt, 29ICD10 via Orphanet, 38MESH via Orphanet, 67UMLS via Orphanet, 35MedGen, 60SNOMED-CT
See all MalaCards sources

Aliases & Descriptions for Lymphangioleiomyomatosis:

Name: Lymphangioleiomyomatosis 50 11 46 24 13 52 68 12 48 66
Lam 46 24 52 68
Lymphangiomyomatosis 11 24 48
Pulmonary Lymphangioleiomyomatosis 11 66
 
Lymphangio-Myomatosis 46 25
Lymphangioleiomyomatosis, Somatic 50
Lung Lymphangioleiomyomatosis 11

Characteristics:

Orphanet epidemiological data:

52
lymphangioleiomyomatosis:
Inheritance: Not applicable; Prevalence: <1/1000000 (Worldwide),1-9/1000000 (Worldwide),<1/1000000 (United States),1-9/1000000 (United States),<1/1000000 (France),1-9/1000000 (Germany),1-9/1000000 (Canada),1-9/1000000 (United Kingdom),1-9/1000000 (Switzerland),1-9/1000000 (New Zealand),1-9/1000000 (Australia),1-9/1000000 (Europe),1-9/1000000 (Netherlands); Age of onset: Adult

Classifications:



External Ids:

OMIM50 606690
Disease Ontology11 DOID:3319
NCIt43 C38153
Orphanet52 ORPHA538
SNOMED-CT60 277844007
ICD10 via Orphanet29 D48.7
MESH via Orphanet38 D018192
UMLS via Orphanet67 C0751674
MedGen35 C0751674

Summaries for Lymphangioleiomyomatosis

About this section
NIH Rare Diseases:46 Lymphangioleiomyomatosis (lim-fan-je-o-li-o-mi-o-ma-to-sis), or lam, is a rare lung disease that mostly affects women in their mid-forties. in lam, an unusual type of cell begins to grow out of control throughout the body, including in the lungs, lymph nodes and vessels, and kidneys. over time, these lam cells form cysts and clusters of cells, which grow throughout the lungs and slowly block the airways. they also destroy the normal lung tissue and replace it with cysts. as a result, air cannot move freely in and out of the lungs, and the lungs cannot supply enough oxygen to the body’s other organs. more than 1 out of every 3 people with lam also develops growths called angiomyolipomas, or amls, in their kidneys. people with lam also may develop:growths in other organs, including the liver and brain large tumors on their lymph nodes there are two forms of lam:sporadic lam, which occurs for unknown reasons lam that occurs in people with a rare inherited disease called tuberous sclerosis complex. this is often a milder form. last updated: 7/16/2013

MalaCards based summary: Lymphangioleiomyomatosis, also known as lam, is related to tuberous sclerosis and breast cancer, and has symptoms including restrictive ventilatory defect, respiratory insufficiency and pulmonary infiltrates. An important gene associated with Lymphangioleiomyomatosis is TSC2 (Tuberous Sclerosis 2), and among its related pathways are TP53 Regulates Metabolic Genes and Thyroid hormone signaling pathway. Affiliated tissues include lung, kidney and lymph node, and related mouse phenotypes are neoplasm and respiratory system.

UniProtKB/Swiss-Prot:68 Lymphangioleiomyomatosis: Progressive and often fatal lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. It affects almost exclusively young women and can occur as an isolated disorder or in association with tuberous sclerosis complex.

Genetics Home Reference:24 Lymphangioleiomyomatosis (LAM) is a condition that affects the lungs, the kidneys, and the lymphatic system. The lymphatic system consists of a network of vessels that transport lymph fluid and immune cells throughout the body.

Wikipedia:69 Lymphangioleiomyomatosis (LAM) is a rare, progressive and systemic disease that typically results in... more...

Description from OMIM:50 606690

Related Diseases for Lymphangioleiomyomatosis

About this section

Diseases in the Lymphangioleiomyomatosis family:

Tsc1-Related Lymphangioleiomyomatosis

Diseases related to Lymphangioleiomyomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 153)
idRelated DiseaseScoreTop Affiliating Genes
1tuberous sclerosis31.9ESR1, PGR
2breast cancer27.5ESR1, MMP1, MMP14, MMP2, MTOR, PGR
3tsc1-related lymphangioleiomyomatosis11.9
4angiomyolipoma10.9
5buschke-ollendorff syndrome10.8TSC1, TSC2
6renal clear cell carcinoma10.8TSC1, TSC2
7vulvar angiokeratoma10.7ESR1, PGR
8central nervous system organ benign neoplasm10.7ESR1, PGR
9spinocerebellar ataxia, autosomal recessive 210.7MTOR, TSC1
10fallopian tube benign neoplasm10.7ESR1, PGR
11appendix leiomyoma10.7ESR1, PGR
12mixed cell adenoma10.7ESR1, PGR
13gelatinous ascites10.7ESR1, PGR
14salpingitis isthmica nodosa10.7DES, ESR1
15deafness, autosomal dominant 8/1210.7ESR1, PGR
16dental enamel hypoplasia10.7ESR1, PGR
17perinatal intestinal perforation10.7ESR1, PGR
18anterograde amnesia10.7DES, PGR
19trigeminal nerve disease10.7ESR1, PGR
20glottis verrucous carcinoma10.7ESR1, PGR
21cerebral atrophy10.7ELN, MMP2
22bartholin's gland adenoid cystic carcinoma10.7ESR1, PGR
23bladder colonic type adenocarcinoma10.7ESR1, PGR
24mollaret meningitis10.7DES, PGR
25deletion 5q3510.6ELN, MMP2
26her2-receptor positive breast cancer10.6ESR1, PGR
27adenocarcinoma in situ10.6ESR1, PGR
28asthma susceptibility 510.6ESR1, PGR
29reading disorder10.6ELN, MMP2
30lymphocytic vasculitis10.6DES, PGR, TSC2
31gallbladder squamous cell carcinoma10.6ESR1, PGR
32parachordoma10.6DES, PGR, TSC2
33amyloid tumor10.6ESR1, PGR
34extracranial neuroblastoma10.6ESR1, PGR
35bartholin's gland benign neoplasm10.6DES, ESR1
36malignant mediastinal neurogenic neoplasm10.6ESR1, PGR
37thoracic benign neoplasm10.6ESR1, PGR, TSC2
38papillary thymic adenocarcinoma10.6ESR1, PGR, TSC2
39pilomyxoid astrocytoma10.6MTOR, TSC1, TSC2
40cauda equina intradural extramedullary astrocytoma10.6MTOR, TSC1, TSC2
41tenosynovitis of foot and ankle10.5MTOR, TSC1, TSC2
42retroperitoneum carcinoma10.5ESR1, PGR
43retinal dystrophies primarily involving bruch's membrane10.5ESR1, MMP2, PGR
44dental caries10.5ESR1, MMP2, PGR
45dysembryoplastic neuroepithelial tumor10.5DES, PGR
46ovarian wilms' cancer10.5ESR1, MMP2, PGR
47capillary disease10.5ESR1, PGR, TSC2
48anisomastia10.5MMP14, MMP2
49pathological gambling10.5MMP1, MMP2
50trachea sarcoma10.5ESR1, MMP2, PGR

Graphical network of the top 20 diseases related to Lymphangioleiomyomatosis:



Diseases related to lymphangioleiomyomatosis

Symptoms for Lymphangioleiomyomatosis

About this section


Clinical features from OMIM:

606690

Symptoms:

 52 (show all 36)
  • abnormality of female internal genitalia
  • hydrocephalus
  • optic atrophy
  • hematuria
  • abnormality of skin pigmentation
  • lymphedema
  • seizures
  • ascites
  • fever
  • abdominal pain
  • restrictive lung disease
  • dyspnea
  • emphysema
  • hemoptysis
  • pneumothorax
  • pulmonary infiltrates
  • recurrent respiratory infections
  • gastrointestinal hemorrhage
  • lymphadenopathy
  • multiple renal cysts
  • renal angiomyolipoma
  • retinal hamartoma
  • shagreen patch
  • renal neoplasm
  • chylothorax
  • chylopericardium
  • abnormal urinary color
  • fatigue
  • macule
  • cough
  • pulmonary lymphangiomyomatosis
  • cognitive impairment
  • chest pain
  • atelectasis
  • abnormality of the lymphatic system
  • ungual fibroma

HPO human phenotypes related to Lymphangioleiomyomatosis:

(show all 30)
id Description Frequency HPO Source Accession
1 restrictive ventilatory defect hallmark (90%) HP:0002091
2 respiratory insufficiency hallmark (90%) HP:0002093
3 pulmonary infiltrates hallmark (90%) HP:0002113
4 chest pain hallmark (90%) HP:0100749
5 multicystic kidney dysplasia typical (50%) HP:0000003
6 abnormality of female internal genitalia typical (50%) HP:0000008
7 hematuria typical (50%) HP:0000790
8 abdominal pain typical (50%) HP:0002027
9 emphysema typical (50%) HP:0002097
10 lymphadenopathy typical (50%) HP:0002716
11 atelectasis typical (50%) HP:0100750
12 ungual fibroma typical (50%) HP:0100804
13 polycystic kidney dysplasia occasional (7.5%) HP:0000113
14 hydrocephalus occasional (7.5%) HP:0000238
15 optic atrophy occasional (7.5%) HP:0000648
16 lymphedema occasional (7.5%) HP:0001004
17 hypermelanotic macule occasional (7.5%) HP:0001034
18 seizures occasional (7.5%) HP:0001250
19 ascites occasional (7.5%) HP:0001541
20 abnormality of the pericardium occasional (7.5%) HP:0001697
21 abnormality of the pleura occasional (7.5%) HP:0002103
22 hemoptysis occasional (7.5%) HP:0002105
23 recurrent respiratory infections occasional (7.5%) HP:0002205
24 gastrointestinal hemorrhage occasional (7.5%) HP:0002239
25 abnormality of temperature regulation occasional (7.5%) HP:0004370
26 retinal hamartoma occasional (7.5%) HP:0009594
27 shagreen patch occasional (7.5%) HP:0009721
28 renal neoplasm occasional (7.5%) HP:0009726
29 cognitive impairment occasional (7.5%) HP:0100543
30 pulmonary lymphangiomyomatosis HP:0012798

UMLS symptoms related to Lymphangioleiomyomatosis:


pain of lymph node

Drugs & Therapeutics for Lymphangioleiomyomatosis

About this section

Drugs for Lymphangioleiomyomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DoxycyclinePhase 4232564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
Doxycycline (INN)
 
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
2
sirolimusPhase 3, Phase 2, Phase 1186353123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
3
MiconazolePhase 3, Phase 2, Phase 1357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
EverolimusPhase 3, Phase 2, Phase 11863159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
5
saracatinibPhase 2, Phase 131
Synonyms:
AZD 0530
 
AZD0530
saracatinib
6
MentholPhase 221842216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
7
LetrozolePhase 2368112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
8
OctreotidePhase 220683150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
9
SomatostatinPhase 221238916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
10
SimvastatinPhase 1, Phase 250379902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
11
CelecoxibPhase 2427169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
12COLANutraceuticalPhase 21824
13
HydroxychloroquinePhase 1141118-42-33652
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
747-36-4 (sulfate (1:1) salt)
AC1L1GEW
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
EINECS 204-249-8
Gen-Hydroxychloroquine 200mg Tablets
HCQ
HMS502P04
Hidroxicloroquina
 
Hidroxicloroquina [INN-Spanish]
Hydroxychlorochin
Hydroxychloroguine
Hydroxychloroquine (INN)
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquine [INN:BAN]
Hydroxychloroquinum
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
ST072188
Spectrum2_001238
Spectrum5_001697
UNII-4QWG6N8QKH
WIN 1258
hydroxychloroquine
14
Progesterone51557-83-05994
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17a-Progesterone
17alpha-Progesterone
17alpha-progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
46665_FLUKA
46665_RIEDEL
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC-700
AC1L1LKF
AI3-51682
Agolutin
Akrolutin
BB_NC-0185
BHR-100
BIDD:ER0547
BIDD:PXR0094
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
Bio-luton
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
CPD000058345
Colprosterone
Corlutin
Corlutina
Corluvite
Corporin
Corpus Luteum Hormone
Corpus luteum hormone
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
DR-2011
Delalutin
Delta(4)-pregnene-3,20-dione
Duraprogen
EINECS 200-350-6
ETI-411
EU-0100895
Endometrin
Estima
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
HSDB 3389
Hormoflaveine
Hormoluton
Hydroxyprogesterone Caproate
Hydroxyprogesterone Caproic acid
LMST02030159
LS-234
Lingusorbs
Lipo-Lutin
Lipolutin
Lopac0_000895
Lucorteum
Lucorteum Sol
Lucorteum sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin M
Lutocyclin
Lutocyclin M
 
Lutocyclin m
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MPA
Membrettes
Methylpregnone
Micronized Progesterone
MolPort-001-794-643
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
NCI60_042166
NSC 64377
NSC 9704
NSC-9704
NSC64377
NSC9704
Nalutron
Natural Progesterone
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
PROGESTERONE
Percutacrine
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Prestwick_411
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, water-soluble
Progesterone-Water Soluble
Progesterone: HBC complex
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Progestérone
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
SR-01000000088
SR-01000000088-5
Spectrum5_002053
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
beta-Progesterone
bmse000482
component of Cyclogesterin
corpus luteum hormone
delta(4)-Pregnene-3,20-dione
delta(Sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta4-Pregnene-3,20-dione
luteohormone
nchembio.2007.53-comp14

Interventional clinical trials:

(show all 30)
idNameStatusNCT IDPhase
1Doxycycline In Lymphangioleiomyomatosis (LAM)CompletedNCT00989742Phase 4
2Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3
3Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)Active, not recruitingNCT00414648Phase 3
4Treatment With Octreotide in Patients With LymphangioleiomyomatosisCompletedNCT00005906Phase 2
5A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With LymphangioleiomyomatosisCompletedNCT01059318Phase 2
6Trial of Aromatase Inhibition in LymphangioleiomyomatosisCompletedNCT01353209Phase 2
7Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00792766Phase 1, Phase 2
8RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1, Phase 2
9Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMCompletedNCT00457808Phase 2
10Nebulized or Inhaled Albuterol for LymphangioleiomyomatosisRecruitingNCT01799538Phase 2
11Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisRecruitingNCT02737202Phase 2
12Safety of Simvastatin in LAM and TSCRecruitingNCT02061397Phase 1, Phase 2
13COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSCRecruitingNCT02484664Phase 2
14Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMActive, not recruitingNCT00490789Phase 2
15The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)CompletedNCT02116712Phase 1
16Safety Study of Sirolimus and Hydroxychloroquine in Women With LymphangioleiomyomatosisCompletedNCT01687179Phase 1
17Pulmonary Hypertension in LymphangioleiomyomatosisCompletedNCT00960895
18Pulmonary Rehabilitation in LymphangioleiomyomatosisCompletedNCT02009241
19Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)CompletedNCT00001869
20Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
21Lymphangioleiomyomatosis (LAM) RegistryCompletedNCT00005486
22National Lymphangioleiomyomatosis Registry, FranceRecruitingNCT01484236
23Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and AngiomyolipomaRecruitingNCT02325505
24Study of the Disease Process of LymphangioleiomyomatosisRecruitingNCT00001465
25Safety and Durability of Sirolimus for Treatment of LAMRecruitingNCT02432560
26Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System DiseasesRecruitingNCT00366509
27The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation PatientsRecruitingNCT02859194
28Lymphatic Anomalies RegistryRecruitingNCT02399527
29Characterization of the Pathogenesis of Primary and Secondary Lymphatic DisordersRecruitingNCT02156115
30Imaging of Lymphatic AnomaliesEnrolling by invitationNCT02744027

Search NIH Clinical Center for Lymphangioleiomyomatosis

Genetic Tests for Lymphangioleiomyomatosis

About this section

Genetic tests related to Lymphangioleiomyomatosis:

id Genetic test Affiliating Genes
1 Lymphangiomyomatosis25

Anatomical Context for Lymphangioleiomyomatosis

About this section

MalaCards organs/tissues related to Lymphangioleiomyomatosis:

34
Lung, Kidney, Lymph node, Smooth muscle, Liver, Brain, Endothelial

Animal Models for Lymphangioleiomyomatosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Lymphangioleiomyomatosis:

39 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.1ESR1, MMP1, MMP2, PGR, RPS6KB1, TSC1
2MP:00053888.0CTSK, ESR1, MMP14, MMP2, MTOR, SRF
3MP:00053807.8ESR1, MMP14, MTOR, PGR, RPS6KB1, SRF
4MP:00053697.2DES, ESR1, MMP14, MMP2, MTOR, MYH10
5MP:00028737.1ESR1, MMP14, MMP2, MTOR, MYH10, PGR
6MP:00053907.0CTSK, ESR1, MMP14, MMP2, MTOR, MYH10
7MP:00053797.0CTSK, ESR1, MMP14, MTOR, PGR, RPS6KB1
8MP:00053976.9CTSK, ESR1, MMP14, MMP2, MTOR, PGR
9MP:00053846.7CTSK, DES, ESR1, MMP14, MTOR, MYH10
10MP:00053866.7DES, ESR1, MMP14, MTOR, MYH10, PGR
11MP:00053856.0DES, ESR1, MMP14, MMP2, MYH10, PGR
12MP:00053875.9CTSK, ESR1, MMP1, MMP14, MMP2, MTOR
13MP:00053785.9CTSK, ESR1, MMP14, MMP2, MTOR, MYH10
14MP:00107685.9DES, ESR1, MMP14, MMP2, MTOR, MYH10
15MP:00053764.2CTSK, DES, ESR1, MMP1, MMP14, MMP2

Publications for Lymphangioleiomyomatosis

About this section

Articles related to Lymphangioleiomyomatosis:

(show top 50)    (show all 606)
idTitleAuthorsYear
1
A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis. (26799509)
2016
2
Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis. (26725158)
2016
3
Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing. (26563443)
2015
4
Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis (LAM). (26432869)
2015
5
Chronic sirolimus therapy for lymphangioleiomyomatosis. (25496098)
2014
6
Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis. (25326562)
2014
7
Clinical features of 280 hospitalized patients with lymphangioleiomyomatosis in Japan. (25385157)
2014
8
Lymphatic manifestations of lymphangioleiomyomatosis. (25507287)
2014
9
Surfactant Dysfunction and Lung Inflammation in the Female Mouse Model of Lymphangioleiomyomatosis (LAM). (25474372)
2014
10
Probable initial pulmonary lymphangioleiomyomatosis and mediastinal lymphangioleiomyoma. (24268918)
2013
11
Tuberous sclerosis presenting with spontaneous pneumothorax secondary to lymphangioleiomyomatosis; previously mistaken for asthma. (23729718)
2013
12
Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis (LAM) on sirolimus. (22117507)
2011
13
Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. (21880281)
2011
14
Lymphangioleiomyomatosis. (21255897)
2011
15
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. (21525172)
2011
16
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. (21774718)
2011
17
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. (20044458)
2010
18
Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). (20235887)
2010
19
Lymphangioleiomyomatosis and TSC2-/- cells. (20235888)
2010
20
A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis. (20235882)
2010
21
Selected case from the Arkadi M. Rywlin International Pathology Slide Seminar: Sporadic lymphangioleiomyomatosis. (20966650)
2010
22
Pregnancy complicated by lymphangioleiomyomatosis. (19249892)
2009
23
Involvement of lymphatics in lymphangioleiomyomatosis. (20143921)
2009
24
New diagnosis and subsequent post-partum radiological improvement of lymphangioleiomyomatosis. (19401495)
2009
25
Caesarean delivery under general anaesthesia for a woman with undiagnosed tuberous sclerosis complex and lymphangioleiomyomatosis. (19157370)
2009
26
Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. (18656809)
2008
27
Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. (18094073)
2008
28
Extrapulmonary lymphangioleiomyomatosis: an unusual cause of biliary tract obstruction. (18219066)
2008
29
Extrapulmonary lymphangioleiomyomatosis presented as the asymptomatic retroperitoneal tumours--two cases report. (17285764)
2006
30
Lymphangioleiomyomatosis. (16707400)
2006
31
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. (16775248)
2006
32
A case of lymphangioleiomyomatosis affecting the supraclavicular lymph nodes. (16628048)
2006
33
The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. (16268919)
2005
34
Pulmonary lymphangioleiomyomatosis in a postmenopausal woman: case report with review of literature. (15861601)
2005
35
Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy. (15209123)
2004
36
Lymphangioleiomyomatosis: a case report and review of the literature. (15656345)
2004
37
Should patients with lymphangioleiomyomatosis undergo screening for meningioma? (15516686)
2004
38
Pulmonary lymphangioleiomyomatosis: a clinicopathological analysis of ten cases. (15148998)
2004
39
Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. (15006970)
2004
40
Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. (12823048)
2003
41
Lymphangioleiomyomatosis. A series of three case reports illustrating the link with high oestrogen states. (11771497)
2001
42
Lymphangioleiomyomatosis: the surgeon's role in diagnosis. (10694627)
2000
43
Oestrogen metabolism in lymphangioleiomyomatosis: catechol-O-methyltransferase pathway is not involved. (10856317)
2000
44
Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. (10460750)
1999
45
Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. (10430739)
1999
46
Lymphangioleiomyomatosis: recurrence after single lung transplantation. (9416700)
1997
47
Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. (8775689)
1996
48
Lymphangioleiomyomatosis and tuberous sclerosis: where is the border? (8729994)
1996
49
Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax. (8620956)
1995
50
Coexisting lymphangioleiomyomatosis and bilateral angiomyolipomas in a patient with tuberous sclerosis. (8189576)
1994

Variations for Lymphangioleiomyomatosis

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lymphangioleiomyomatosis:

68
id Symbol AA change Variation ID SNP ID
1TSC2p.Arg611GlnVAR_005650

Clinvar genetic disease variations for Lymphangioleiomyomatosis:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TSC2NM_000548.4(TSC2): c.5024C> T (p.Pro1675Leu)single nucleotide variantPathogenicrs45483392GRCh37Chr 16, 2137898: 2137898
2TSC2NM_000548.4(TSC2): c.1513C> T (p.Arg505Ter)single nucleotide variantPathogenicrs45517179GRCh37Chr 16, 2114342: 2114342
3TSC2NM_000548.4(TSC2): c.1832G> A (p.Arg611Gln)single nucleotide variantPathogenicrs28934872GRCh37Chr 16, 2120572: 2120572
4TSC2NM_000548.4(TSC2): c.1096G> T (p.Glu366Ter)single nucleotide variantPathogenicrs45517148GRCh37Chr 16, 2110791: 2110791
5TSC2NM_000548.4(TSC2): c.5238_5255del18 (p.His1746_Arg1751del)deletionPathogenicrs137854218GRCh37Chr 16, 2138305: 2138322
6TSC1NM_000368.4(TSC1): c.491G> A (p.Trp164Ter)single nucleotide variantPathogenicrs118203387GRCh37Chr 9, 135798752: 135798752
7TSC1NM_000368.4(TSC1): c.495C> A (p.Cys165Ter)single nucleotide variantPathogenicrs118203388GRCh37Chr 9, 135798748: 135798748

Expression for genes affiliated with Lymphangioleiomyomatosis

About this section
Search GEO for disease gene expression data for Lymphangioleiomyomatosis.

Pathways for genes affiliated with Lymphangioleiomyomatosis

About this section

Pathways related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

(show all 35)
idSuper pathwaysScoreTop Affiliating Genes
19.8MTOR, TSC1, TSC2
29.8ESR1, MTOR, TSC2
3
Show member pathways
9.6VEGFC, VEGFD
49.5ESR1, MTOR, TSC1, TSC2
5
Show member pathways
9.5MTOR, RPS6KB1, TSC2
69.5MTOR, RPS6KB1, TSC2
7
Show member pathways
9.5MMP1, MTOR, TSC1, TSC2
89.4ESR1, MTOR, RPS6KB1
99.4ESR1, MTOR, RPS6KB1
109.4SRF, TSC2
119.4MMP1, MMP14, MMP2
12
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
13
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
14
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
15
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
16
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
17
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
18
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
19
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
209.3MTOR, RPS6KB1, TSC1, TSC2
219.3MTOR, RPS6KB1, TSC1, TSC2
229.3MTOR, RPS6KB1, TSC1, TSC2
239.3MMP2, VEGFC, VEGFD
24
Show member pathways
9.2MMP2, MTOR, RPS6KB1, TSC2
259.2ESR1, MMP1, MTOR, TSC1, TSC2
269.2ESR1, MMP2, MTOR, RPS6KB1
27
Show member pathways
8.9CTSK, MMP1, MMP14, MMP2
288.7MMP1, MMP2, MTOR, VEGFC, VEGFD
29
Show member pathways
8.5ESR1, MMP14, MMP2, MTOR, RPS6KB1, TSC2
30
Show member pathways
8.5CTSK, ELN, MMP1, MMP14, MMP2
318.5MTOR, RPS6KB1, SRF, TSC1, TSC2
32
Show member pathways
8.4MTOR, RPS6KB1, TSC1, TSC2, VEGFC, VEGFD
338.4MTOR, RPS6KB1, TSC1, TSC2, VEGFC, VEGFD
34
Show member pathways
8.3ESR1, RPS6KB1, TSC1, TSC2, VEGFC, VEGFD
35
Show member pathways
6.8DES, ELN, ESR1, MTOR, MYH10, SRF

GO Terms for genes affiliated with Lymphangioleiomyomatosis

About this section

Cellular components related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1TSC1-TSC2 complexGO:003359610.7TSC1, TSC2
2extracellular regionGO:00055767.7CTSK, ELN, MMP1, MMP2, PMEL, VEGFC

Biological processes related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of macroautophagyGO:001624210.5MTOR, TSC1
2positive regulation of myotube differentiationGO:001083110.3MMP14, MTOR
3negative regulation of cell sizeGO:004579210.2MTOR, TSC1
4regulation of vascular endothelial growth factor receptor signaling pathwayGO:003094710.1VEGFC, VEGFD
5positive regulation of mast cell chemotaxisGO:006075410.1VEGFC, VEGFD
6negative regulation of insulin receptor signaling pathwayGO:004662710.0RPS6KB1, TSC1, TSC2
7intramembranous ossificationGO:000195710.0CTSK, MMP2
8response to insulinGO:00328689.9MTOR, RPS6KB1, TSC1
9induction of positive chemotaxisGO:00509309.9VEGFC, VEGFD
10TOR signalingGO:00319299.8MTOR, RPS6KB1
11cardiac myofibril assemblyGO:00550039.7MYH10, SRF
12positive chemotaxisGO:00509189.7TSC2, VEGFC, VEGFD
13stress fiber assemblyGO:00431499.6ELN, SRF
14collagen catabolic processGO:00305749.2CTSK, MMP1, MMP14, MMP2
15angiogenesisGO:00015258.9MMP14, MMP2, VEGFC, VEGFD
16long-term memoryGO:00076168.9MTOR, RPS6KB1, SRF
17extracellular matrix disassemblyGO:00226178.6CTSK, ELN, MMP1, MMP14, MMP2
18response to hypoxiaGO:00016668.0MMP14, MMP2, SRF, VEGFD

Molecular functions related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1vascular endothelial growth factor receptor 3 bindingGO:004318510.3VEGFC, VEGFD
2metalloendopeptidase activityGO:000422210.1MMP1, MMP14, MMP2
3serine-type endopeptidase activityGO:00042529.3CTSK, MMP1, MMP14, MMP2
4protein bindingGO:00055154.4CTSK, DES, ELN, ESR1, MMP14, MMP2

Sources for Lymphangioleiomyomatosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet